Draft:Etripamil
Medication
From Wikipedia, the free encyclopedia
Etripamil (brand name Cardamyst) is a novel, fast-acting non-dihydropyridine L-type calcium channel blocker, designed as intranasal (nasal spray) for the on-demand treatment of paroxysmal supraventricular tachycardia (PSVT). It represents a major shift in managing this condition, moving therapy from the hospital to the patient's home. Developed by Milestone Pharmaceuticals, it is the first of its kind, offering a practical and rapid solution to a long-standing medical problem. It is considered a breakthrough nasal spray for a common heart condition.[1]
Submission declined on 9 December 2025 by Theroadislong (talk).
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
| Submission declined on 12 November 2025 by Significa liberdade (talk). This draft is not written from a neutral point of view. Wikipedia articles must be written neutrally in a formal, impersonal, and dispassionate way. They should not read like a blog post, advertisement, or fan page. Rewrite the draft to remove:
Declined by Significa liberdade 4 months ago.
| |
 | This is a draft article. It is a work in progress open to editing by anyone. Please ensure core content policies are met before publishing it as a live Wikipedia article. Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL Last edited by Theroadislong (talk | contribs) 3 months ago. (Update)
Finished drafting? |
 | |
| Clinical data | |
|---|---|
| Trade names | Cardamyst |
| Other names | (-)-MSP-2017 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C27H36N2O4 |
| Molar mass | 452.595 g·mol−1 |
| 3D model (JSmol) | |
| |
When sprayed into the nose, etripamil is rapidly absorbed into the bloodstream. It travels to the heart and specifically targets the AV node. By blocking calcium channels in this node, etripamil slows down the speed of the electrical signals. Etripamil slows down the heart and breaks the loop, which allows it to return to its normal rhythm (normal sinus rhythm).
Clinical evidence and efficacy
Etripamil's effectiveness has been proven in large-scale clinical trials, most notably the RAPID trial. The key findings from these studies showed that:
- High conversion rate: A significantly higher percentage of patients who used etripamil successfully converted back to a normal heart rhythm within 30 minutes compared to those who used a placebo. Studies showed a conversion rate of around 64% for etripamil versus 31% for placebo.[2]
- Rapid onset of action: For most patients, the medication worked quickly, with the median time to conversion being approximately 15-20 minutes.[3]
This strong clinical evidence demonstrates that etripamil is both effective and reliable for its intended use.
Furthermore, research is underway to explore etripamil's use in other heart rhythm conditions, particularly Atrial Fibrillation with Rapid Ventricular Response (AFib-RVR). In this condition, the AV node is also bombarded with rapid signals, and etripamil's ability to slow conduction could be highly beneficial.[4][5]
Administration and safety
Using etripamil is designed to be straightforward for patients during a stressful PSVT episode. The patient, preferably while sitting or lying down, administers one spray into each nostril.
The most common side effects are typically mild and localized to the nose, such as nasal congestion, discomfort, or a runny nose. Because it is administered nasally and acts quickly, it has a lower risk of causing the widespread systemic side effects that can be seen with intravenous medications.[6]
The most significant advantage of etripamil is patient empowerment. It reduces the anxiety and helplessness associated with PSVT episodes and drastically cuts down on costly and time-consuming emergency room visits.[7]
Wikipedia articles must be written neutrally in a formal, impersonal, and dispassionate way. They should not read like a blog post, advertisement, or fan page. Rewrite the draft to remove:
Instead, only summarize in your own words a range of independent, reliable, published sources that discuss the subject.
If you have a conflict of interest (e.g. you are the subject, an employee, or a relative) or are being paid to edit, you must disclose this to comply with Wikipedia's Terms of Use.